SG
UTHR icon

Sankala Group’s United Therapeutics UTHR Stock Holding History

Sankala Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9K Hold
26
– – 0.01% 342
2025
Q4 		$13.1K Buy
+26
New +$12.1K 0.01% 353

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Sankala Group's UTHR Position: Q1 2026 in Review

Sankala Group held its United Therapeutics (UTHR) position steady in Q1 2026 at 26 shares worth $13.9K. The position accounts for 0.01% of the portfolio, ranked #342.

Sankala Group first reported a position in UTHR in Q4 2025 and has held it in 2 quarters since. 852 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Sankala Group held 26 shares of United Therapeutics worth $13.9K as of Q1 2026.
  • Sankala Group left its United Therapeutics share count unchanged in Q1 2026.
  • United Therapeutics made up 0.01% of Sankala Group's portfolio in Q1 2026, its #342 holding.
  • Sankala Group first reported a position in United Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 852 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.